论文部分内容阅读
目的 :观察拉米夫定治疗深度黄疸慢性乙型肝炎的临床疗效。方法 :随机将 4 5例 (HBVDNA阳性和HBeAg)慢性乙型肝炎病人分为治疗组和对照组 ,两组均给予相同的护肝药物治疗 ,治疗组加用拉米夫定抗病毒治疗 ,疗程 6个月。结果 :6个月疗程后治疗组病人临床症状明显改善 ,HBVDNA阴转率和肝功能复常率比对照组明显增高 (86 .95 %对 9.0 9% ,5 6 .5 2 %对 2 7.2 7% ,6 5 .2 2 %对 31.82 % ,P <0 .0 5 ) ,结论 :拉米夫定治疗慢性重型乙型肝炎近期临床效果良好且安全。
Objective: To observe the clinical efficacy of lamivudine in treating chronic jaundice and chronic hepatitis B. Methods: Forty five patients (HBVDNA positive and HBeAg) with chronic hepatitis B were randomly divided into treatment group and control group. Both groups were treated with the same hepatoprotective drugs. The treatment group was treated with lamivudine antiviral therapy. The treatment course 6 months. Results: After 6 months of treatment, the clinical symptoms of patients in the treatment group were significantly improved. The negative rate of HBVDNA and the rate of recovery of liver function were significantly higher than those in the control group (86.95% vs 9.09%, 5.62% vs 7.27% %, 65.22% vs 31.82%, P <0.05). Conclusion: Lamivudine is effective and safe in the treatment of chronic severe hepatitis B in the near future.